The Kaposi's Sarcoma-associated Herpesvirus (KSHV)-encoded G-protein coupled receptor (vGPCR) is an oncoprotein that is implicated in KSHV-associated malignancies. We previously revealed vGPCR incorporates sulfate groups within its extracellular N-terminal tyrosine residues (Y26 and Y28) and that this tyrosine sulfation is crucial for its tumorigenicity in nude mice. hGRO- binds vGPCR in a sulfotyrosine-dependent manner and promotes its tumorigenicity through autocrine signaling. Interestingly, an unsulfated vGPCR mutant (yydd-vGPCR) attenuated the tumor growth triggered by hGRO-. In this study, the extracellular N-terminus of vGPCR (wt-vGN) and an unsulfated vGPCR mutant (yydd-vGN) were individually secreted, expressed and purified. A radioactive labeling assay demonstrated that wt-vGN but not yydd-vGN incorporated [
Kaposi's sarcoma (KS) is an angioproliferative neoplasm consisting of characteristic spindle cells and infiltrating leukocytes, and is a leading cause of morbidity and mortality among the AIDS population. The Kaposi's sarcomaassociated herpesvirus (KSHV, also known as human herpesvirus 8, or HHV-8) is the etiologic agent for Kaposi's sarcoma (KS), as well as primary effusion lymphoma and multicentric Castleman's disease [1] [2] [3] [4] . KSHV is a DNA virus and belongs to the gamma-2 herpesvirus family, and is closely related to herpesvirus saimiri (HVS) and rhesus monkey rhadinovirus (RRV). The genome of KSHV is approximately 165-170 kb and contains more than 80 open reading frames. As one of several recently identified human tumor viruses, KSHV has been extensively studied to elucidate the mechanism of its tumorigenicity. Indeed, the KSHV genome encodes an array of proteins that are implicated in modulating host inflammatory responses, angiogenesis and tumor formation, most notably the G proteincoupled receptor (vGPCR or ORF74) [5] [6] [7] .
vGPCR is the homolog of human interleukin-8 receptor (IL-8R or CXCR2). However, unlike its cellular counterpart, it is constitutively activated even in the absence of ligand association [8] . vGPCR triggers downstream signaling components including the phospholipase C pathway, and PI3 kinase/AKT axis, and has broad signaling effects in vitro, activating NF-B, NFAT and AP-1 [9] [10] [11] [12] [13] [14] . Emerging evidence supports that this KHSV lytic gene is an oncogene: vGPCR-transformed cells led to tumorigenesis in nude mice and vGPCR transgenic mice developed the human KS-like disease [15, 16] .
vGPCR constitutively activates downstream signaling even without ligand association. However, chemokines such as GRO- and IP-10 bind vGPCR and modulate its signaling. Accumulating evidence suggests that the N-terminus of vGPCR is important for its chemokine association and tumorigenicity [17] [18] [19] [20] . Understanding the molecular details of vGPCR association with chemokines will advance our knowledge of the regulatory mechanisms that govern vGPCR signaling and tumorigenesis and will inform the efforts to develop therapy targeting vGPCR in the treatment of KS.
Our previous study showed that vGPCR contains sulfated tyrosine residues at the N-terminus (Y26 and Y28), which are necessary for GRO- but not IP-10 binding. Sulfotyrosines at positions 26 and 28 are not critical for signaling downstream of vGPCR. However, they are crucial for the tumorigenicity of vGPCR in nude mice and human GRO- (hGRO-) promotes vGPCR tumorigenesis in a sulfotyrosine-dependent manner. Unsulfated yydd-vGPCR (in which the tyrosines at positions 26 and 28 have been mutated to aspartic acid) was not tumorigenic in nude mice [21] . Interestingly, the tumor forming ability of NIH3T3 cells expressing hGRO- was consistently reduced by yydd-vGPCR expression [21] , which implied yydd-vGPCR (more precisely its unsulfated extracellular N-terminus) decreased the tumorigenicity of hGRO-.
In this study, chimeras comprising the extracellular N-terminus of vGPCR or yydd-vGPCR and mouse Fc (fragment, crystallizable) region were constructed (wt-vGNmFc and yydd-vGN-mFc, respectively). These fusion proteins were individually secreted, expressed and purified by affinity chromatography from whole cell lysates or the media supernatant. Radioactive labeling demonstrated that wt-vGN-mFc but not yydd-vGN-mFc recruited [ 35 S]-sulfate. In nude mice experiments, the tumor forming ability of NIH3T3 cells expressing hGRO- was consistently reduced by the expression of yydd-vGN-mFc but not by wt-vGNmFc expression. Also, the tumorigenicity of vGPCR in vivo was reduced by yydd-vGN-mFc. All these data support the conclusion that the unsulfated extracellular N-terminus of vGPCR reduces the tumorigenicity of hGRO- in vivo. For lentiviral vector constructs, wt-vGN-mFc or yyddvGN-mFc were excised and cloned into pCDH-CMV-EF-Puro (System Bioscience) between the Nhe I and Pme I sites (CDH-wt-vGN-mFc and CDH-yydd-vGN-mFc accordingly). Lentivirus containing wt-vGN-mFc or yydd-vGNmFc was made as described previously and NIH3T3 cells stably expressing wt-vGN-mFc or yydd-vGN-mFc were established as previously [22] . For the secreted expression of wt-vGN-mFc or yyddvGN-mFc, 2 mL of media from CDH-wt-vGN-mFc or CDH-yydd-vGN-mFc transfected 293T cells seeded in 6-well-plates was used in affinity chromatography, while 20 L eluate of each sample was obtained and used for immunoblotting.
Expression and purification of wt-vGN and yyddvGN

Immunoblotting
Immunoblot assays were performed as previously described [21] . Immunoblot detection of the wt-vGN-mFc and yydd-vGN-mFc was performed either with anti-Penta.His antibody (1:2500; Sigma) or with secondary antibody (goat anti-mouse IgG peroxidase conjugate) alone. ]-sulfate for 10 h. Labeled cells were lysed and used in affinity chromatography. The eluate was used for autoradiography as previously described [22] .
Labeling of wt-vGN and yydd-vGN
Tumor formation assays in nude mice
All animal experiments were carried out according to the institutional ethical guidelines for animal experiments at the Guangzhou Institute of Medicine and Health, Chinese Academy of Sciences. NIH3T3 cells stably expressing the empty vector (CDH-CMV-EF-Puro) and NIH3T3 cells stably expressing vGPCR, hGRO-, wt-vGN-mFc or yyddvGN-mFc were injected subcutaneously into the flanks of 3-to 5-week-old mice (athymic, nude/nude). Nude mice were sacrificed four weeks after inoculation, and the tumor weights were determined as described before [22] .
Total RNA was isolated from the tumors and cDNA was prepared using the kit according to the manufacturer's instructions (Invitrogen, Shanghai, China). The expression of hGRO-, vGPCR, wt-vGN-mFc and yydd-vGN-mFc mRNA in the tumors was detected by RT-PCR, as previously reported [21, 22] .
Results
wt-vGN but not yydd-vGN is modified by sulfation
pSecTag2A-wt-vGN-mFc and pSecTag2A-yydd-vGN-mFc contained the vGN-mFc chimera, in which the Ig leader sequence was upstream of the DNA fragment (vGN) encoding 1-49 amino acids of vGPCR or yydd-vGPCR, and the mFc fragment with 6×His.tag tail was fused to the 3′ end of vGN (Figure 1 ). The vGN-mFc chimeras of CDH-wtvGN-mFc or CDH-yydd-vGN-mFc were identical to their pSecTag2A counterparts apart from the restriction sites.
293T cells were transfected with pSecTag-wt-vGN-mFc or pSecTag-yydd-vGN-mFc. wt-vGN-mFc and yydd-vGNmFc were purified and used for CBB staining or immunoblotting. One exclusive band of approximately 40-45 kD was identifid by CBB staining for each sample, matching the predicted size of wt-vGN-mFc or yydd-vGN-mFc ( Figure  2 ). The wt-vGN-mFc band was of a weaker intensity than that of yydd-vGN-mFc, implying lower expression levels. Immunoblotting with anti-Penta His antibody verified that the purified proteins were wt-vGN-mFc and yydd-vGNmFc. Immunoblotting without primary antibody demonstrated that both wt-vGN-mFc and yydd-vGN-mFc were secreted into the media. Additionally, the band for yydd-vGN-mFc was wider than that of wt-vGN-mFc, which correlated with the CCB staining result (Figure 2) .
The results of ; coomassie brilliant blue staining (bottom). B, 5% input for Penta-his IB (upper); 5% input for actin immunoblotting (middle); eluate from media supernatant for immunoblotting, in which only the goat anti-mouse IgG peroxidase secondary conjugate was used (bottom). CBB staining: coomassie brilliant blue staining. Wt, wt-vGN-mFc; yydd, yydd-vGN-mFc; wcl, whole cell lysate; media, media supernatant. modifications.
Unsulfated vGN reduces the tumorigenicity of hGRO- in nude mice
In our previous study, the average tumor weight of the nude mice injected with NIH3T3/hGRO- cells mixed with NIH3T3/yydd-vGPCR cells was only 38% of that of nude mice injected with NIH3T3/hGRO- cells alone [21] . This suggested that yydd-vGPCR (precisely its unsulfated extracellular N-terminus) could affect the tumorigenicity of hGRO-. To investigate if the unsulfated N-terminus of yydd-vGPCR reduces the tumorigenicity of hGRO-, nude mice were subcutaneously injected with NIH3T3 cells stably expressing hGRO-, wt-vGN-mFc, or yydd-vGN-mFc ( Table 1 ). The average tumor weight of the hGRO- group was 1571.625 mg, 1994.875 mg for the hGRO-/wt-vGN group and 602.4 mg for the hGRO-/yydd-vGN group ( Figure 3A) , demonstrating that the tumorigenicity of hGRO- was greatly reduced by yydd-vGN but not wt-vGN. RT-PCR showed that hGRO-, wt-vGN and yydd-vGN were well expressed in the nude mouse tumors ( Figure 3B ). The average tumor weight of hGRO-/yydd-vGN group was only 38% of that of the hGRO- group and the tumor weight of the hGRO-/wt-vGN group was 125% of that of the hGRO- group. These data correlated with our previous data, in which the average tumor weight of the hGRO-/ yydd-vGPCR group was only 38% of that of the hGRO- group [21] . 
Unsulfated vGN reduces the tumorigenicity of vGPCR in nude mice
Our previous study demonstrated that hGRO- binds vGPCR in a sulfotyrosine-dependent manner, and suggested that hGRO- promotes vGPCR tumorigenicity through autocrine signaling. To further test if the unsulfated N-terminus of yydd-vGPCR affects hGRO- autocrine signaling in vGPCR tumorigenicity, nude mice were subcutaneously injected with NIH3T3 cells stably expressing vGPCR, wt-vGN-mFc, or yydd-vGN-mFc ( Table 2 ). The average tumor weight of the vGPCR group was 659.5 mg, 685 mg for the vGPCR/wt-vGN group and 417.5 mg for the vGPCR/yydd-vGN group ( Figure 4A ). RT-PCR confirmed good expression of vGPCR, wt-vGN and yydd-vGN in the nude mouse tumors ( Figure 4B ). The average tumor weight of the vGPCR/yydd-vGN group was 60% of that of the vGPCR group and the average tumor weight of the vGPCR/wt-vGN group was almost identical (105%) to that of the vGPCR group. These data support the conclusion that unsulfated yydd-vGN inhibits vGPCR tumorigenicity in nude mice.
Discussion
vGPCR is a bona fide signaling molecule that is implicated in KSHV-associated malignancies. This seven membranespanning protein is constitutively activated; however, ligand association upregulates (GRO-) or downregulates (IP-10) its signaling. Our previous study revealed that tyrosine sulfation on Y26 and Y28 of the N-terminus of vGPCR is crucial for GRO-α but not IP-10 association. An unsulfated YYDD mutant (yydd-vGPCR) demonstrated similar signaling as that of wild-type vGPCR, however, the tumorigenicity of yydd-vGPCR in nude mice completely disappeared. A mode of action was proposed based on our previous study, whereby hGRO- promotes signaling and tumorigenicity in a sulfotyrosine-dependent manner [21] . Interestingly, in nude mice experiments, when NIH3T3 cells expressing yydd-vGPCR were mixed with hGRO- expressing NIH3T3 cells, the tumorigenicity of hGRO- was reduced by 60% compared with the hGRO- only group. Thus, we hypothesized that these important residues of the extracellular N-terminus of vGPCR might facilitate hGRO- to associate with its other cell surface-expressing receptors (named GR here) and regulate their signaling. hGRO- could not associate with yydd-vGPCR and the unsulfated N-terminus of this molecule might block hGRO- association with GR through some unknown mechanism. This could explain why the average tumor weight of nude mice injected with NIH3T3 cells expressing yydd-vGPCR mixed with NIH3T3 cells expressing hGRO- was much reduced compared with those injected with NIH3T3 hGRO- cells alone.
yydd-vGN-mFc and wt-vGN-mFc were expressed and purified in this study to investigate if the unsulfated extracellular N-terminus of vGPCR negatively regulates the tumorigenicity of hGRO-. mFc was introduced to facilitate the expression and characterization of the secreted peptides. The [
35 S]-sulfate labeling assay verified that wt-vGN-mFc but not yydd-vGN-mFc has the tyrosine sulfation modification, which implies these two peptides are suitable for in vivo studies mimicking the N-terminus of wt-vGPCR and yydd-vGPCR accordingly.
Injection of nude mice with NIH3T3 cells expressing hGRO- mixed with NIH3T3/yydd-vGN-mFc cells resulted in far smaller tumors than injection with NIH3T3/hGRO- cells. Furthermore, the average tumor weight of the hGRO-/wt-vGN group was higher (125%) than that of the hGRO- only group. This correlated with our previous data. This may be because wt-vGN-mFc enhances the association of hGRO- with GR. However, it cannot function as a receptor and promote tumor formation through an autocrine pathway as vGPCR does, which may explain why the average tumor weight of the hGRO-/vGPCR group is almost two fold that of the hGRO- group plus the vGPCR group in our previous study.
hGRO- promotes vGPCR tumorigenicity through autocrine signaling and yydd-vGN could attenuate the tumorigenicity of hGRO-, implying that the tumorigenicity of vGPCR expressing NIH3T3 cells could be affected by blocking hGRO- association with its cellular receptor. Nude mice data verified this possibility, in which the average tumor weight of vGPCR/yydd-vGN group was 60% of that of the vGPCR group, and the average tumor weight of the vGPCR/wt-vGN group was almost identical (104%) to that of vGPCR group (Figure 4) .
Based on the data generated in this study and our previous study, we present a model in which the tumorigenicity of hGRO- is diminished by the unsulfated extracellular N-terminal region of vGPCR ( Figure 5 ). In this model, the extracellular N-terminus of vGPCR associates with hGRO- to promote hGRO- association with its cellular receptor. Its unsulfated counterpart, the N-terminus of yydd-vGPCR, cannot bind hGRO- and can block hGRO- association with its cellular receptor. We hypothesize that vGPCR has two docking sites in its intracellular N-terminus, which can associate with hGRO- and the cell surface hGRO- receptor (GR) separately. The sulfation modification at the N-terminus of vGPCR works like a "swivel clamp" in the scaffold to "fasten" hGRO- to GR, enabling binding between hGRO- and GR. In contrast, the N-terminus of yyddvGPCR could not bind hGRO- because of the loss of the sulfotyrosines. However, it could still occupy the docking site in GR and inhibit hGRO- association with GR, explaining why yydd-vGPCR could reduce the tumorigenicity of hGRO- in vivo. Secreted yydd-vGN, which has the same sequence and a similar structure to the unsulfated N-terminus of yydd-vGPCR, could reduce the tumorigenicity of hGRO- and reduce the tumorigenicity of vGPCR in nude mice by blocking the hGRO- association with its cellular receptor (GR). This provides a good opportunity for the development of therapeutic agents targeting hGRO- that could be applied to the treatment of cancers caused by KSHV vGPCR or abnormal hGRO- expression.
